Conclusive test results prove pulmonary device provides far higher efficacy than cigarettes. In a study of 30 test subjects, participants achieved much higher nicotine blood levels at faster rates than those possible from smoking cigarettes: without receiving any of the deadly carcinogens. Each subject received less nicotine than typically inhaled from smoking one cigarette: with greater psychoactive effects.
Cigarettes, which are more addictive than cocaine, will kill more than 600 million people over the next thirty years.
Advertisement
Next Safety's revolutionary new device, allows those addicted to tobacco a mechanism to receive nicotine with the high psycho active effects provided by smoking, without inhaling the sixty-nine known carcinogens contained in cigarettes and harming others with second-hand smoke.
In this study smokers achieved mean nicotine venous blood level increases of 28.4 nanograms per milliliter less than ten seconds after inhalation.
![Pubs Propose to Sell Nicotine Gum Patches]( "Pubs Propose to Sell Nicotine Gum Patches")
Britain- The pub hopes to benefit from the smoking ban and they are already stocking on nicotine patches and gums for the success of the ban.
Nonsmokers do not have the same diffusion barrier caused by the inhalation and subsequent deposition of cigarette combustion byproducts in the lungs, which smokers have. Therefore, nonsmokers achieved nicotine blood levels of 158 nanograms per milliliter in less than ten seconds after inhalation (laboratory analysis performed by NMS Labs).
This breakthrough in pulmonary drug delivery is not limited to only nicotine. Any drug soluble in water can now be delivered with very high efficacy and efficiency utilizing Next Safety's proprietary pulmonary devices and methods. Treatments enabled by the technology include the efficient and high efficacy delivery of numerous drugs never before effectively delivered through pulmonary means. For example, in the announced nicotine results, more than 74 percent of the nicotine contained in the device entered the blood stream. Many drugs currently delivered only through IV or injection in important classes such as antibiotics, analgesics and anti medics along with certain vaccinations can now be delivered with very high precision, efficacy and efficiency.
Next Safety moved into a new 32,000 square ft facility on July 27th.
During the following eighteen months the company expects to occupy 850,000 square feet of additional office/manufacturing space and hire approximately 3,600 employees.
Next Safety's nicotine delivery device will be priced at less than US$100.00, with refills costing less than ten percent of the average pack of cigarettes in developed countries on a nicotine equivalent basis. The company will begin shipping devices to markets where current regulations allow in December. Next Safety will ship more than two million nicotine delivery devices per month during the first quarter of 2008.
The company will begin sampling devices to certain reporters in Boston on Wednesday, August 15th, on Thursday, August 15th and in New York on Monday, August 20th. In addition, the company will hold a moderated discussion at the Mandarin Oriental in New York on Tuesday, August 21st. Attendees will include: leading pulmonologists, reporters and public officials, as well as smokers and non-smokers.
Source: PRWIRE
SRM/S
Pubs Propose to Sell Nicotine Gum Patches
Britain- The pub hopes to benefit from the smoking ban and they are already stocking on nicotine patches and gums for the success of the ban.
Advertisement
Nonsmokers do not have the same diffusion barrier caused by the inhalation and subsequent deposition of cigarette combustion byproducts in the lungs, which smokers have. Therefore, nonsmokers achieved nicotine blood levels of 158 nanograms per milliliter in less than ten seconds after inhalation (laboratory analysis performed by NMS Labs).
This breakthrough in pulmonary drug delivery is not limited to only nicotine. Any drug soluble in water can now be delivered with very high efficacy and efficiency utilizing Next Safety's proprietary pulmonary devices and methods. Treatments enabled by the technology include the efficient and high efficacy delivery of numerous drugs never before effectively delivered through pulmonary means. For example, in the announced nicotine results, more than 74 percent of the nicotine contained in the device entered the blood stream. Many drugs currently delivered only through IV or injection in important classes such as antibiotics, analgesics and anti medics along with certain vaccinations can now be delivered with very high precision, efficacy and efficiency.
Next Safety moved into a new 32,000 square ft facility on July 27th.
During the following eighteen months the company expects to occupy 850,000 square feet of additional office/manufacturing space and hire approximately 3,600 employees.
Next Safety's nicotine delivery device will be priced at less than US$100.00, with refills costing less than ten percent of the average pack of cigarettes in developed countries on a nicotine equivalent basis. The company will begin shipping devices to markets where current regulations allow in December. Next Safety will ship more than two million nicotine delivery devices per month during the first quarter of 2008.
The company will begin sampling devices to certain reporters in Boston on Wednesday, August 15th, on Thursday, August 15th and in New York on Monday, August 20th. In addition, the company will hold a moderated discussion at the Mandarin Oriental in New York on Tuesday, August 21st. Attendees will include: leading pulmonologists, reporters and public officials, as well as smokers and non-smokers.
Source: PRWIRE
SRM/S
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest General Health News
Direct coastal access may represent a viable route to public health promotion, but the relationships of coastal living are not strongest among lower-income groups.
New research by Tinnitus UK has found that over four million gardeners are putting their hearing capacity at risk this summer without using safety protection.
Mucus plugs could be targeted to help reduce fatalities from chronic obstructive pulmonary disease.
The development of reliable curative therapies for multiple sclerosis could significantly reduce the economic burden of the disease on patients and wider society.
A genetic variant in a patient protected from autosomal dominant Alzheimer's disease (ADAD) suggests a role for RELN signaling in resilience to dementia.